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Abstract
Vaccinia Tian Tan (VTT) was attenuated by deletion of the TC7L-TK2L and TA35R genes to generate MVTT3. The mutant was
generated by replacing the open reading frames by a gene encoding enhanced green fluorescent protein (EGFP) flanked by
loxP sites. Viruses expressing EGFP were then screened for and purified by serial plaque formation. In a second step the
marker EGFP gene was removed by transfecting cells with a plasmid encoding cre recombinase and selecting for viruses
that had lost the EGFP phenotype. The MVTT3 mutant was shown to be avirulent and immunogenic. These results support
the conclusion that TC7L-TK2L and TA35R deletion mutants can be used as safe viral vectors or as platform for vaccines.
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Introduction
Vaccinia virus Tian Tan (VTT) strain has been studied for use
as a live viral vector for infectious diseases or cancer therapy [1].
The VTT viral vector has been evaluated for vaccine development
[2,3,4], but has issues relating to mild complications [5,6,7].
Therefore, the use, efficacy, and safety of the VTT strain requires
re-evaluation [8,9,10]. Since the strain remains lethal to mice after
intracranial inoculation, its use as a vaccine vector for humans is
limited [5], and further attenuation of VTT will be necessary for
its development as a useful vaccine vector.
Researchers are increasingly utilizing conditional gene manip-
ulation strategies that allow deletion of a gene of interest [11]. One
such approach is cumulative site-specific gene integration using
the Cre-loxP recombination system. Among the site-specific gene
recombination systems, the Cre-loxP system has been well studied
and widely used for site-specific recombination in animal cells
and functional analysis of genes [12,13]. Cre recombinase recog-
nizes a specific 34 bp loxP target sequence and catalyzes site-
specific and irreversible cleavage of DNA segments flanked by
unique loxP sequences. The enzyme catalyzes deletion, inversion,
and exchange reactions depending on the number and direction
of loxP sites inserted. In contrast to classical in vivo knockout
strategies, which result in complete deletion of gene function in the
whole organism, this conditional gene-targeting technology
involving the recombinase-mediated cassette enables cell type-
specific deletion of genes by driving the expression of Cre
recombinase under the control of a cell type-specific promoter
[14].
In the present study, we constructed a modified VTT genome
(MVTT3) by deleting both TC7L-TK2L and TA35R genes,
which resulted in reduced virulence. Deletion of small DNA
fragments (3–25 nucleotides) are common in poxviruses [15].
Tartaglia et al deleted the C7L to K2L region (12ORFs) in the
Copenhagen strain of vaccinia virus and reported phenotypic
attenuation [16]. Rachel L. Roper showed A35R has little
homology to any protein outside of poxviruses, suggesting a novel
virulence mechanism [17]. Here, we examine the mutant virus
which removed both TC7L-TK2L (15,262–25,450) including
TC7L, TC6L, TC5L, TC4L, TC3L, TC2L, TC1L, TN1L,
TN2L, TM1L, TM2L, TK1L, and TK2L and a single open
reading frame TA35R (138,881–139,570) from vaccinia Tian Tan
strain in relation to its virulence in vitro and in vivo [18,19].
Materials and Methods
Cells, viruses and animals
BHK-21 hamster kidney cells, PK(15) porcine kidney cells,
HeLa human cervical adenocarcinoma epithelial cells, Madin-
Darby canine kidney (MDCK) epithelial cells, and Vero African
green monkey kidney cells were obtained from the China Center
for Type Culture Collection. The BHK-21 and PK(15) cells were
cultured in modified Eagle’s medium (MEM). HeLa and MDCK
cells were cultured in Dulbecco’s MEM. The Vero cells were
cultured in RPMI 1640. Culture media (Invitrogen, Beijing,
China) for the HeLa, MDCK, and Vero cells were supplemented
with 10% fetal bovine serum (FBS; Hyclone, Beijing, China), 100
units/ml benzyl penicillin, and 100 mg/ml streptomycin sulfate.
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5% FBS, 100 units/ml benzyl penicillin, and 100 mg/ml
streptomycin sulfate. The parental vaccinia Tian Tan (GenBank
accession no. AF095689) strain was obtained from the Institute of
Virology at the Chinese Center for Disease Control and
Prevention. Three- to five-week-old female BALB/c mice and
female New Zealand white rabbits were purchased from the
Experimental Animal Center of the Academy of Military Medical
Sciences of China. The animal experimental protocols were
approved by the Institutional Animal Care and Use Committee
(IACUC) of the Chinese Academy of Military Medical Science,
Changchun, China (10ZDGG007). All surgery was performed
under sodium pentobarbital anesthesia, and all efforts were made
to minimize suffering.
Construction of VTT transfer vectors pSK-PTC7L-TK2L-
EGFP and pSK-PTA35R-EGFP
The plasmid pVAX1-Cre, a derivative of pVAX1, was provided
by Xiaoming Xia. Standard gene synthesis techniques were used
to construct shuttle plasmid pSK-PTC7L-TK2L-EGFP and pSK-
PTA35R-EGFP. A DNA fragment containing TC7L–loxP–PE/
L–EGFP–loxP–TK2L sites was constructed by Shanghai Generay
Biotech Co., Ltd. The PE/L–EGFP cassette was flanked by
similarly oriented loxP sites. Replacement of the TC7L-TK2L
gene by EGFP was confirmed using TC7LSP (59-GTA CAT GAG
TCT GAG TTC CTT G-39) and TK2LASP (59-ATC TGG CTA
TTC TCC TTA GTT G-39) as primers. The shuttle plasmid
pSK-PTA35R-EGFP was constructed using the same strategy
described above, with primers TA35RSP (59-CAG CGT GAT
TCT TAC CAG ATA TT-39) and TA35RASP (59-TGT TGC
GAG CAT TAC TGC GTT TA-39). The sequence flanked by the
TC7L-TK2L gene was amplified to confirm the deletion of EGFP
using TC7LSP1 (59-CTT TGT GTA TCA TAT TCG TCC C-
39) and TK2LASP1 (59- AAT TAG CGT CTC GTT TCA GAC
T-39) as primers. The sequence flanked by the TA35R gene was
amplified to confirm the deletion of EGFP, using primers
TA35RSP1 (59- ACG AAT TAC ATT TCT TGT T-39) and
TA35RASP1 (59- GCT ATG ATA TCT CTG GCT A-39).
Construction of MVTT1
Homologous recombination resulting in TC7L-TK2L replaced
by the EGFP open reading frame (ORF) generated recombinant
MVTT1-EGFP. This was accomplished by infecting 80%
confluent BHK-21 cells with an input multiplicity of infection
(MOI) of 0.01 PFU VTT per cell [20]. At 2 h post-infection, the
cells were transfected with 2–3 mg of pSK-PTC7L-TK2L-EGFP
in 10 ml of Lipofectamine 2000 (Invitrogen). Forty-eight hours
after co-transfection at 37uC, virus was released by three freeze–
thaw cycles and used for further infection and selection.
Fluorescing plaques i.e., expressing MVTT1-EGFP were picked
under an inverted fluorescence microscope and purified by 5
cycles of plaque isolation. The purity of the grown mutant was
verified by PCR amplification and sequencing of the gene region
flanking and within the TC7L-TK2L. MVTT1-EGFP genomic
DNA was harvested using a Genomic DNA Miniprep kit (Axygen
Biosciences). The PCR was carried out using MVTT1-EGFP
genomic DNA as template and the primers TC7LSP and
TK2LASP through 30 cycles of 95uC for 5 min, 94uC for 30 s,
55uC for 45 s, and 72uC for 45 s with the last extension at 72uC
for 10 min. The product was resolved by 1% agarose gel
electrophoresis.
BHK-21 cells (1610
4) were infected with 100 PFU MVTT1-
EGFP. At 2 h post-infection, the cells were transfected with shuttle
plasmid pVAX1-Cre. Forty-eight hours after co-transfection, non-
EGFP-expressing plaques were picked and isolated by five rounds
of plaque purification. The MVTT1 was propagated in BHK-21
cells. PCR amplification was used to confirm the deletion of
EGFP. The MVTT1 genomic DNA was extracted as template,
the primers TC7LSP1 and TK2LASP1 through 30 cycles at 95uC
for 5 min, 94uC for 30 s, 55uC for 45 s, and 72uC for 45 s with the
last extension at 72uC for 10 min. The product was resolved by
1% agarose gel electrophoresis.
Construction of MVTT2
Recombinant MVTT2 was constructed using the same strategy
described above. The TA35R gene was knocked out successively
by homologous recombination with pSK-PTA35R-EGFP, and
removal of EGFP by the Cre-loxP system. The double deletions
were confirmed using the same PCR amplifications as shown
above.
Construction of MVTT3
The MVTT1 strain was used in a second homologous
recombination. A similar procedure was used to delete the
TA35R ORF from the MVTT1 strain to form MVTT3. The
double deletions were confirmed using the same PCR amplifica-
tion as it was shown above.
Genetic stability of the mutants
Monslayers of BHK-21 cells were infected with the three
mutants at 100 PFU and serially passaged 10 times to evaluate
their genetic stability [21]. PCR and oligonucleotides flanking the
regions deleted were used to demonstrate consistent amplification
of the corresponding regions.
Cell viability assay
The test used 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide (MTT; Sigma, St. Louis, MO). The BHK-21,
MDCK, HeLa, Vero, and PK(15) cells were seeded in 96-well
plates (1610
4 cells/well) 1 d before they were infected with various
concentrations (0.05 MOI) of MVTT1, MVTT2, MVTT3, or
VTT. The viability of the five cell lines were tested every 24 h by
treating cells with 20 ml of MTT (5 mg/ml) and incubating for 4 h
at 37uC. The culture medium was removed, and the formed
crystals were dissolved by exposing the cells in each well to 150 ml
dimethylsulfoxide for 10 min at 37uC. The absorbance of the
suspension at 490 nm was measured by an enzyme-linked
immunosorbent assay (ELISA) plate reader. Untreated cells were
used as controls, and all samples were examined thrice. The cell
survival rate was calculated using the following formula:
1006(Experiment absorbances)/(control absorbances) [22,23].
Crystal violet staining
To test the spread efficiently of mutants in different cells,
plaques of the mutants were visualized by crystal violet staining.
The three mutants MVTT1, MVTT2 and MVTT3 at 0.05 PFU/
cell were added to the five cell lines in 12-well plates. The cells
were overlaid with 1% agarose after 90 min of viral exposure and
then incubated for another 48 h at 37uC. Cellular growth was
stopped by removing the medium, and 0.5% crystal violet in 20%
methanol was added to the cells for 10 minutes. CPE was
visualized by removing the crystal violet.
Titration of mutants
The five cell lines infected with VTT and the mutants, and the
viruses were harvested after 96 h and titrated in BHK-21 cells.
Titers of the mutants in different cell lines were determined by
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suspension [24].
Virulence assay
For the rabbit skin pathogenicity assay, three concentrations
(10
6,1 0
7, and 10
8 pfu in 0.1 ml sterile PBS) of MVTT1, MVTT2,
MVTT3, or VTT were injected intradermally on the shaved backs
of rabbits. Each concentration was performed in three rabbits.
The diameters of erythema resulting from inoculation were
measured daily for 18 d.
Mutant virulence was evaluated by measuring the weight loss of
inbred BALB/c mice after viral inoculation, according to a
previously described method [25]. Groups of five-week-old mice
were inoculated intranasally with 10
5,1 0
6,o r1 0
7 pfu of MVTT1,
MVTT2, MVTT3, or VTT in 20 ml of sterile PBS. Body weights
of each mouse were determined daily for 25 d [26,27]. Uninfected
mice were included as controls.
Intracranial 50% lethal infectious dose (ICLD50)
measurement
Twelve groups of 3-week-old female BALB/c mice (n=6) were
inoculated intracranially with 10
5,1 0
6,o r1 0
7 pfu of MVTT1,
MVTT2, MVTT3, or VTT in 10 ml of sterile PBS and deaths
were recorded daily for 14 d. ICLD50’s were calculated using the
Reed–Muench method [28].
Immunogenicity and efficacy in vivo
Groups of 6-week-old female BALB/c mice (n=10) were
injected intramuscularly (i.m.) with 5610
4 PFU/mouse of
MVTT1, MVTT2, MVTT3 or VTT in 0.1 ml PBS, or mock
infected with PBS. Three weeks later, sera were taken from caudal
vein and each mouse received a booster of the same dose. Two
weeks later, the animals were euthanized and samples of heat-
inactivated sera were processed for mouse IL-2, IL-4, IL-10 or
IFN-c ELISA analysis using commercially kits (Groundwork
Biotechnology Diagnosticate, USA).
To determine the in vivo efficacy of MVTT1, MVTT2 and
MVTT3, 3-week-old female BALB/c mice (n=10) were vacci-
nated intramuscularly as described above and 4 weeks later
infected intranasally with 5006LD50 VTT strain [29]. Indivi-
dual body weights were measured daily, and animals with a weight
loss of .30% were killed. Uninfected mice were included as
controls.
Figure 1. Schematic representation of the MVTT3 genome and identification of mutants. (A) The TC7L-TK2L and TA35R genomic
deletions were found in the viral genome. (B) EGFP was expressed by mutants MVTT1-EGFP, MVTT2-EGFP, or MVTT3-EGFP in the BHK-21 cells. The
virus-infected cells were visualized by isolated fluorescent plaque, which was recognized in the same visual fields. Non-fluorescent plaques appeared
because of recombinant MVTT1, MVTT2, or MVTT3 in the BHK-21 cells. All photos were taken at 2006magnification.
doi:10.1371/journal.pone.0031979.g001
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Heat-inactivated mouse serum were serially diluted in twofold
steps, mixed with the parental VTT virus strain at a concentration
of 100 PFU per well, and transferred to a monolayer of BHK-21
cells. 96 h post-incubation, BHK-21 cells were inspected for
cytopathic effects. IC50 were determined by the highest dilution of
mouse serum that generated 50% viral plaque reduction and was
calculated by the method of Reed and Muench [28].
Results
Generation of the mutants
TC7L-TK2L and TA35R genes were deleted in VTT genome
to generate three mutants (Fig. 1A). Plaques containing mutants
were recognized by their fluorescence, and mutants were clonally
purified in the BHK-21 cells by repeated plaque isolation (Fig. 1B).
Fig. 2A showed that the double deletions 366 bp (9,357–9,732) of
TC7L-TK2L and 353 bp (139,162–139,515) of TA35R were
successful based on the PCR results for the plaque-purified EGFP
virus.
Clones of purified non-fluorescent plaque in which TC7L-
TK2L, TA35R, and both TC7L-TK2L and TA35R were deleted
were identified (Fig. 1B). 431 bp (14,886–25,471) correct viral
sequences flanking the deletion sites of TC7L-TK2L and 1142 bp
(137,883–139,679) correct viral sequences flanking the deletion
sites of TA35R were confirmed by nucleotide sequencing after
removal of EGFP. Fig. 2B showed that the double deletions were
successful based on the PCR results for the generation of three
deletion viral mutants from VTT, namely, MVTT1, MVTT2 and
MVTT3.
Genetic stability of the mutants
The three mutants were added to cultures of BHK-21 cells
passaged 10 times at 1 day intervals to determine their stability.
The three genomic DNAs were then analyzed for the presence of
TC7L-TK2L and TA35R. The mutant MVTT1 could not
transcribe the gene within TC7L-TK2L after 2, 4, 6, 8, and 10
passages in BHK-21 cells, contrary to the result of VTT (Fig. 2C).
Similar results were obtained with MVTT2 and MVTT3 (Fig. 2D
and G). The correct 431 bp and 1142 bp viral sequences flanking
the deletion sites of TC7L-TK2L and TA35R respectively were
confirmed by nucleotide sequencing after 2, 4, 6, 8, and 10
passages. These findings indicate that the mutants were genetically
stable after many passages (Fig. 2 E, F and H). This characteristic
was crucial for eliminating the non-essential genes in developing a
lower virulence vector for human use.
Figure 2. PCR analysis results of the TC7L-TK2L and TA35R
genes of the isolated mutant. Diagnostic PCR was performed to
identify the final mutant. The deletion of the TC7L-TK2L and TA35R
genes was investigated by PCR 72 h after infection of BHK-21 cells with
0.01 MOI of wild-type VTT. Approximately 366 bp (TC7L-TK2L; A, lane 1)
and 353 bp (TA35R; A, lane 3) were detected by ethidium bromide
staining. In addition, the TC7L-TK2L and TA35R fragments were missing
in the mutants MVTT1-EGFP (TC7L-TK2L; A, lane 2), MVTT2-EGFP (TA35R;
A, lane 4), and MVTT3-EGFP (TC7L-TK2L and TA35R; A, lane 5 and lane
6). The genes 431 bp flanking the TC7L-TK2L regions (B, MVTT1, lane 1;
and MVTT3, lane 3) and the genes 1142 bp flanking the TA35R regions
(B, MVTT2, lane 2; and MVTT3, lane 4) were investigated to identify non-
EGFP-expressing virus. Evaluation of the genetic stability in the BHK-21
cells after 2, 4, 6, 8 and 10 passages. TC7L-TK2L gene of MVTT1 (C, lanes
2–6), TA35R gene of MVTT2 (D, lane 2–6), TC7L-TK2L gene of MVTT3 (G,
lanes 3–7), and TA35R gene of MVTT3 (G, lanes 8–12) produced
negative results, comparing to positive PCR results. The genes of MVTT1
flanking the TC7L-TK2L regions (E), the genes of MVTT2 flanking the
TA35R regions (F), and the genes of MVTT3 flanking the TC7L-TK2L
regions (H, lanes 1–5) or TA35R regions (H, lanes 6–10) were detected
correctly.
doi:10.1371/journal.pone.0031979.g002
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The MTT colorimetric assay was performed to detect viabilities
of the five cell lines after infection (Fig. 3). When cells were treated
with the four viruses, MVTT3 had little effect on cell viability. In
contrast, MVTT1, MVTT2 and VTT inhibited growth by 5%–
50%, 45%–55% and 60%–80% after 96 h, respectively; growth of
cells treated with VTT was eventually completely blocked.
Therefore, the survival rates of the five cell lines infected with
VTT were significantly lower than those infected with the
mutants. The survival rate of cells infected with MVTT3 was
higher than those infected with the other two mutants. The
survival rate of cells infected with MVTT1 was higher than that of
cells infected with MVTT2. Similar results were obtained by tests
using crystal violet staining of the five cell lines infected with the
mutants (Fig. 4).
Mutants spread efficiently in five cell lines
The five mammalian cell lines were infected with 0.05 PFU/cell
of each virus. Based on crystal violet staining, each cell type tested
was found to be infected by VTT. Compared with VTT, MVTT3
apparently did not produce cytopathic effect in PK(15), MDCK,
HeLa, and Vero cells (Fig. 4). The MVTT3 virus, however,
displayed lower spread than MVTT1 (Fig. 4). The spread of
MVTT1 evidently decreased than MVTT2, and MVTT2
displayed lower spread than VTT in all five cell lines, indicating
that deletion of TC7L-TK2L further attenuated the virus (Fig. 4).
These results also indicate that the loss of viral genomic fragments
TC7L-TK2L or TA35R may not spread efficiently in tissue
culture.
Grown of mutants
All three mutants proved capable of growing in the BHK-21
cells. The titration was shown in Fig. 5. The titers of the mutant
viruses in each cell were lower than that of the parental virus. The
titer of MVTT3 was lower than MVTT2 and MVTT1.
Deletion of the TC7L-TK2L or TA35R gene attenuates VTT
virulence in rabbits
Cutaneous lesion is a side effect of the virus inoculation;
therefore, virulence was further assessed by intradermal inocula-
tion on the rabbit dorsal spine. The lesion diameters were
measured 18 d after inoculation. The diameters of the central
lesions normally reached their peak on day 7. The diameters when
the erythemas reached their peak are presented in Fig. 6A. The
average differences in largest lesion diameter caused by each
mutant were compared against that produced by VTT (Fig. 6B).
The largest lesion size for each rabbit was shown in Fig. 6C.
Rabbit skin remained intact when inoculated with varied doses of
Figure 3. Assessment of growth of five cell lines infected with the mutants. Effects of MVTT1, MVTT2, MVTT3, or VTT (0.05 PFU/cell) and
infection times on the cell viabilities of HeLa (A), MDCK (B), PK(15) (C), BHK-21 (D), and Vero (E). Cells were seeded in 96-well plates (1610
4 cells/well)
one day before they were infected with 0.05 PFU/cell of MVTT1, MVTT2, MVTT3, or VTT. Cell viability was measured daily for 4 d by MTT colorimetric
assay. All measurements were performed in triplicate. Data are presented as mean 6 SD.
doi:10.1371/journal.pone.0031979.g003
A Novel VTT Attenuation Vector
PLoS ONE | www.plosone.org 5 February 2012 | Volume 7 | Issue 2 | e31979MVTT3, whereas the rabbit immunized with VTT developed a
severe rash even when administered a dose of 10
6 pfu. This was
similar to the result of inoculation of 10
8 pfu MVTT1. No
significant difference between the lesions formed by MVTT1 and
MVTT2 were observed (P.0.05). Recovery from skin lesions
caused by VTT was slower than recovery caused by MVTT1 and
MVTT2. The extent of recovery from lesions caused by MVTT1
was better than recovery from that caused by MVTT2.
MVTT3 is safe for BALB/c mice
Groups of six mice were infected with 10
5,1 0
6,o r1 0
7 PFU of
MVTT1, MVTT2, and MVTT3 deletion mutants or VTT
intranasally, and weight loss was recorded daily. As shown in
Fig. 7, all mice survived during a period of 25 d. We show the first
11days after infection, which has significant differences between
mutants group and VTT group. In contrast to the mice that
received PBS, mice infected with MVTT1, MVTT2, or MVTT3
deletion mutants showed mild signs of illness, and mice in the
MVTT3groupgained weightmorequicklythandidthemiceinthe
other two groups. However, in contrast to VTT, there was an
evident positive correlation between the dose of virus inoculation
and the body weight loss. The VTT group had more severe signs of
illness, and weight loss reached 12.19% on day 9. The lowest dose
of 10
5 pfu of VTT resulted in a significant body weight loss. The
three mutants were likely attenuated by at least about 100-fold. The
weight gain rate of MVTT3 was similar as PBS group. The weight
gain rate of MVTT3 was higher than MVTT1 and MVTT2.
These results suggest that MVTT1, MVTT2, and MVTT3 viruses
were attenuated with respect to its parent VTT, and that the
virulence of MVTT3 was less than that of the other strains. This
experiment was repeated twice with similar results obtained.
In vivo virulence of MVTT3
Six 3-week-old BALB/c mice were infected via the intracranial
route to evaluate the neurovirulence of the three recombinant
strains (Fig. 8). Since the ICLD50 of MVTT2 was 2.5610
5 pfu and
that of VTT was 3.1610
3 PFU, MVTT2 was significantly
attenuated by 80-fold. No mortality was observed in the mice
infected with MVTT1 and MVTT3 although they were given the
highest dose of 10
7 pfu. These indicate that MVTT1 and MVTT3
were attenuated by at least 3,200-fold relative to the ICLD50 of
Figure 4. Plaque phenotypes formed by infection with mutant viruses. Confluent monolayers of PK(15), MDCK, HeLa, BHK-21 and Vero cells
in 12-well plates were infected with 0.05 PFU/cell of MVTT1, MVTT2, MVTT3, or VTT viruses. The plates were incubated at 37uC for 2 d prior to staining
with 0.1% crystal violet. The pathogenicity of MVTT1, MVTT2, and MVTT3 apparently decreased in all five cell lines (compared with VTT as the control).
doi:10.1371/journal.pone.0031979.g004
Figure 5. Virus titer of mutants in five cell lines tested. PK(15),
MDCK, HeLa, BHK-21 and Vero cells infected with 0.05 MOI of VTT and
the mutants, and then the viruses were harvested and titrated in BHK-
21 cells. Virus titer was determined by measuring the plaque assays.
doi:10.1371/journal.pone.0031979.g005
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data indicate that the MVTT2 mutant exhibited attenuated but to
a lesser degree than the MVTT1 and MVTT3 mutants. The
results of the ICLD50 were consistent with those from the
intranasal infection experiment. This experiment was repeated
twice with similar results obtained.
Immunogenicity of mutants
Delivery of MVTT1, MVTT2, MVTT3 and VTT elicited
strong systemic immune responses induced by i.m. vaccination.
IL-2, IL-4, IL-10 and IFN-c responses, as measured by mouse
ELISA, were already detectable using a spectrophotometer (Fig. 9).
Mice were infected and on week three and five serum were
harvested for IL-2, IL-4, IL-10 and IFN-c production. The groups
of MVTT1, MVTT2, MVTT3 and VTT, after twice adminis-
tration, remained robust immune responses than PBS group. IL-
10 responses was more difficult to induce. No significant response
was seen after second immunization. For monitoring the
production of IL-2, IL-4, and IFN-c, responses were enhanced
consecutively in twice i.m.-immunized. The difference among the
mutants was not significant.
Neutralizing antibody titer against the parental vector VTT was
shown in Fig. 10. Immunization of each group induced systemic
neutralizing antibody using the dose of 5610
4 PFU/mouse. The
second immunization marked effects on level of neutralizing
antibody. Neutralizing antibody titers of mutants are similar to
those with the parental strain (P.0.05). Collectively, these results
demonstrated that both mutants and VTT can induce robust
systemic immune responses.
Mutants protects mice from pathogenic VTT strain
challenge
The protective immunogenicities of 5610
4 PFU MVTT1,
MVTT2 and MVTT3 were determined by using a mouse model
challenged with a highly pathogenic VTT strain. The mice
immunized with MVTT1, MVTT2 and MVTT3 did not exhibit
any significant differences in weight post challenge and no signs of
illness. In contrast, beginning at the week of infection, all the mice
in the PBS group clearly showed clinical signs of disseminated
disease, such as ruffling fur and arched back. All mice immunized
of MVTT1, MVTT2 or MVTT3 survived, whereas all sham-
immunized mice were killed from 7 days because of a 30% weight
loss (Fig. 11). All three mutants were equally effective in protection
of mice against challenge with the VTT strain. These data support
the conclusion that a VTT-based vaccine without TC7L-TK2L
and TA35R genes would be a efficacious and immunogenic
vaccine.
Discussion
VTT was used as a vaccine against smallpox in China for
millions of people, but remains neurovirulent in mice [5]. In this
manuscript, we present the initial characterization of the TC7L-
TK2L and TA35R deletion mutants in VTT to be avirulent. As
previous study shows, the removal of the viral M1L-K2L genes
(MVTT2-GFP) was less virulent than VTT for 340-fold by
determining the ICLD50 value in mice [6]. Furthermore, the
removal of the viral C2L to F3L genes (MVTTZCI) was attenuated
for 1000-fold [30]. However, MVTT1 was attenuated by at least
Figure 6. Characterization of virulence of strains intradermally injected in rabbits. Each rabbit was inoculated intradermally on the dorsal
spine with a 10-fold dilution of MVTT1, MVTT2, MVTT3, or VTT (10
6,1 0
7, and 10
8 pfu). The central size diameters were recorded 18 d after inoculation.
The diameters when erythemas reached their peak for each rabbit (A and C) are presented. The average difference is shown between lesion diameter
produced by each recombinant and that by VTT (B). The data represents the mean 6 SD of three lesions. The mean lesion sizes produced by MVTT1
and MVTT2 were significantly smaller than those formed by parental VTT. Lesions did not develop after inoculation with MVTT3 at the three doses.
doi:10.1371/journal.pone.0031979.g006
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virulent than MVTT2-GFP and MVTTZCI. Others deleted C12L
(10-fold) and A53R (4.6-fold) genes to be less virulent [31]. Base on
VTT, this strategy enhance the attenuation potency. MVA [32]
and NYVAC [33], as recombinant poxvirus vector, were highly
attenuated to provide greater safety in humans. NYVAC was
deleted of 18 specific open reading frames including the C7L-K1L
genes [16]. No detectable induration or ulceration at the site of
inoculation on rabbit skin [16]. This result was similar with
MVTT3. Cutaneous lesion, more or less, could be seen after
charged with MVTT1 or MVTT2 (Fig. 6). Not surprisingly,
TA35R gene played a role in virulence [17]. We demonstrated
that MVTT2 was attenuated by 80-fold. Base on MVTT1, the
deletion of TA35R gene was one step closer to attenuation.
Moreover, body weight changes were not significant, when mice
were infected with the highest dose (Fig. 7). MVA is apathogenic in
vivo, and virulence was clearly decreased in the same way [34]. Six
major deletions emerged in the MVA genome [35]. Beside, C7L,
C6L, N2L and K2L genes were deleted which were not associated
with virulence in previous report. Because of the complexity of
vaccinia viruses and the variety of combinational genes deletion
reported, it was not yet possible to make a definitive statement
about the correct gene of the most attenuation phenomenon.
However, compared with attenuated strains such as the NYVAC,
MVA and other VTT mutants, they all show attenuation in
varying degrees.
The phenotypic changes observed in mutants were related to
the loss of the TC7L-TK2L and TA35R genes in the VTT
genome. As previous study shows, the loss of M1L-K2L genes
reduced cell-to-cell spread including HeLa, PK(15), MDCK and
Vero cells [6]. The loss of C2L to F3L genes reduced cell-to-cell
spread including MDCK and Vero cells [30]. Consistent with
previous findings, the titers of mutants changed significantly, and
cell-to-cell spread was reduced in vitro. Of the genes, K1L and
C7L prevent eIF2a phosphorylation to inhibit cellular and viral
protein synthesis in modified VACV Ankara (MVA) infection [36].
K2L gene encode a serine protease inhibitor that inhibits cell–cell
fusion [37]. In short, the titers and spread efficiency of MVTT1
and MVTT3 were decreased (Fig. 4). Nevertheless, C2L and A35
gene were not required for viral replication in vitro [17,38].
Pathology of MVTT2 infected cells was slighter than VTT group
(Fig. 4).
Vaccine candidates not only had strongly diminished virulence,
but also maintaining good immunogenicity. Both MVA and
NYVAC gave roughly comparable levels of protection against
pathogenic vaccinia [39,40]. During the generation of the
attenuated NYVAC and MVA strains, some of those immuno-
modulatory genes were deleted or disrupted and this might explain
why both viruses were highly immunogenic. The immunogenicity
Figure 7. Virulence of MVTT1, MVTT2, and MVTT3 in mice after
intranasal inoculations. Groups of mice (n=6) were infected
intranasally with different doses of MVTT1, MVTT2, MVTT3,VTT, or PBS
on day 0, at doses of 10
5 pfu (A), 10
6 pfu (B), and 10
7 pfu (C). The mean
group weight was expressed as the percentage of the mean body
weight change. The error bar indicates the standard deviation of each
group. Each dose group of VTT and mutant showed a significant
difference in weight change (P,0.05). No mice in the MVTT3 and PBS
group lost weight or showed signs of illness.
doi:10.1371/journal.pone.0031979.g007
Figure 8. Protection from lethal challenge. Six 3-week-old mice in
each dilution group were inoculated intracranially with 10
5,1 0
6, and
10
7 pfu of MVTT3 and VTT (A), and MVTT1 and MVTT2 (B). The survival
rate of animals were observed for 14 d. All mice inoculated with MVTT1,
MVTT3 and10
5 pfu of MVTT2 survived. All mice infected with 10
6 and
10
7 pfu of MVTT2 and VTT died.
doi:10.1371/journal.pone.0031979.g008
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the C7L gene [41]. While, others demonstrate that C7L and K1L
antagonize eIF2a phosphorylation, prevent PKR activation and
inhibit antiviral activities [36,42]. Furthermore, deleting C6L gene
in MVA could improve the immunogenicity. Few studies showed
that N2L and K2L were associated with immunogenicity in
previous report. We therefore removed TC7L-TK2L gene from
VTT in hopes of identifying its immunogenicity. Here, we
demonstrated mutants induced immune responses was equal to
those induced by VTT immunization. Deletion of the A35 gene
resulted in increased immunogenicity in previous studies [29,43].
Our study shows deletion of TA35R gene couldn’t decrease
immunogenicity of Modified VTT stain, which could be
alternative vaccine vector. MVTT3 won’t decrease immunoge-
nicity significantly by genome remodel. It would be important to
determine whether or not MVTT3 could protect animals against
pathogenic VTT strain challenge. MVTT3 protect mice effec-
tively from the challenge of a massive dose of VTT, suggesting that
Figure 9. Immune responses induced by vaccination. Ten 6-week-old BALB/c mice received 5610
4 PFU MVTT1, MVTT2 or MVTT3 by
intramuscular route and three weeks later received booster of the same dose in 0.1 ml of PBS. The serum were harvested on weeks 3 and 5 post
infection (i.m.). Shown were induced IL-2, IL-4, IL-10 and IFN-csystemic immune responses in the two vaccinated cohorts as measured by mouse ELISA
kit analysis. All measurements were performed in triplicate. Data were presented as mean 6 SD.
doi:10.1371/journal.pone.0031979.g009
Figure 10. Neutralization antibody titer in murine sera. Murine
sera collected at 3 and 5 weeks after infection. Neutralization antibody
titer was calculated by determining the highest serum dilution to
generated 50% viral plaque reduction. All measurements were
performed in triplicate. Data were presented as mean 6 SD.
doi:10.1371/journal.pone.0031979.g010
Figure 11. Protection of mice against pathogenic vaccinia VTT
strain challenge. Groups of ten BALB/c mice (3-week-old) were
vaccinated with 5610
4 PFU MVTT1, MVTT2 or MVTT3 via intramuscular
routes. Mice received PBS were included as controls. Four weeks post-
immunization, the mice were challenged intranasally with 5006LD50
VTT strain. Cross marks indicate the mice that were killed because of a
30% weight loss. Data show average percent change in pre-challenge
weigh. The error bar indicates the standard deviation (SD) of animals
from each group.
doi:10.1371/journal.pone.0031979.g011
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Tan strain-based vaccines will keep their immunogenicity. Since
MVTT3 may offer greater advantage for avirulent and immuno-
genic, this strain could be used as an alternative, safer viral vector
and vaccine for infectious diseases and cancer.
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